LATEST NEWS

January 30, 2024
DIAGNODE 3 STUDY: DIABETES VACCINE DIAMYD® (GAD65-ALUM) IN PEOPLE WITH HLA DR3-DQ2 HAPLOTYPE
Earlier we reported publication of the first results of the Diagnode-1 and Diagnode-2 studies, testing Diamyd Medical's diabetes vaccine GAD-alum (Diamyd®) in people with recently diagnosed type 1 diabetes. Diamyd Medical is now recruiting people for the Diagnode 3 study.
June 20, 2023
UPDATE PUBLICATIONS
We have updated the Diabeter Research website with a number of publications of studies in which Diabeter authors were involved:
April 12, 2023
UPDATE PSYCHOLOGY PUBLICATIONS 2022-2023
We have updated the Diabeter Research website with a number of publications of studies in which Diabeter psychologist Giesje Nefs was involved:
July 4, 2022
UPDATE PUBLICATIONS FIRST HALF OF 2022
We have updated the Diabeter Research website with a number of publications of studies in which Diabeter, or employees of Diabeter, were involved
January 25, 2022
UPDATE PUBLICATIONS 2021/2022
We have updated the Diabeter Research website with a number of publications of studies in which Diabeter, or employees of Diabeter, were involved
November 17, 2021
CONSENSUS STATEMENT DO-IT-YOURSELF AUTOMATED INSULIN DELIVERY SYSTEMS
Recently a consensus statement on the use of open-source insulin delivery (AID) systems was published. Diabeter pediatrician Per Winterdijk, himself an open-source AID system user, contributed to the statement
November 10, 2021
LIFE EXPECTANCY, MORTALITY, PREVENTION OF COMPLICATIONS AND HOPE
Disturbing statistics on diabetes were presented in the Dutch press in October 2021
October 4, 2021
FIRST PUBLICATION OF JDRF-PROJECT ‘BIOMARKERS OF HETEROGENEITY IN TYPE 1 DIABETES’
C-peptide and impaired awareness of glycemia
June 1, 2021
PROGRESS TOWARDS PREVENTION OF TYPE 1 DIABETES: TEPLIZUMAB
Approval of Teplizumab for further application and development
February 21, 2020
NEWS FROM ATTD 2020
© 2023 Diabeter | Terms of Use | Privacy Statement